ImmuPharma plc (IMM.L)
GBp 3.44
(-1.85%)
GBp 3.44
(-1.85%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.06 Million GBP | -1.12% |
| 2022 | -3.02 Million GBP | 54.02% |
| 2021 | -6.58 Million GBP | -17.85% |
| 2020 | -5.58 Million GBP | 11.02% |
| 2019 | -6.28 Million GBP | 22.26% |
| 2018 | -8.08 Million GBP | -11.7% |
| 2017 | -7.23 Million GBP | -9.79% |
| 2016 | -6.58 Million GBP | -44.4% |
| 2015 | -4.56 Million GBP | -33.23% |
| 2014 | -3.42 Million GBP | 19.0% |
| 2013 | -4.22 Million GBP | -1.27% |
| 2012 | -4.17 Million GBP | -8.84% |
| 2011 | -3.83 Million GBP | 8.23% |
| 2010 | -4.18 Million GBP | -140.59% |
| 2009 | 10.29 Million GBP | 325.11% |
| 2008 | -4.57 Million GBP | -29.68% |
| 2007 | -3.52 Million GBP | 0.0% |
| 2005 | -1.53 Million GBP | -5189.66% |
| 2004 | -29 Thousand GBP | -93.33% |
| 2003 | -15 Thousand GBP | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -382.11 Thousand GBP | 0.0% |
| 2024 Q1 | -382.11 Thousand GBP | 56.69% |
| 2023 Q3 | -882.29 Thousand GBP | 32.05% |
| 2023 Q1 | -649.2 Thousand GBP | 52.24% |
| 2023 FY | -3.18 Million GBP | -5.08% |
| 2023 Q4 | -882.29 Thousand GBP | 0.0% |
| 2023 Q2 | -1.29 Million GBP | -100.0% |
| 2022 Q1 | -834.75 Thousand GBP | 62.66% |
| 2022 FY | -3.02 Million GBP | 54.02% |
| 2022 Q2 | -1.66 Million GBP | -100.0% |
| 2022 Q3 | -679.72 Thousand GBP | 59.29% |
| 2022 Q4 | -1.35 Million GBP | -100.0% |
| 2021 Q1 | -1.11 Million GBP | 59.12% |
| 2021 Q2 | -3.08 Million GBP | -175.82% |
| 2021 Q3 | -1.46 Million GBP | 52.5% |
| 2021 Q4 | -2.23 Million GBP | -52.81% |
| 2021 FY | -6.58 Million GBP | -17.85% |
| 2020 Q3 | -1.36 Million GBP | 52.2% |
| 2020 Q2 | -2.85 Million GBP | -100.0% |
| 2020 FY | -5.58 Million GBP | 11.02% |
| 2020 Q1 | -1.42 Million GBP | 54.11% |
| 2020 Q4 | -2.73 Million GBP | -100.0% |
| 2019 Q1 | -1.64 Million GBP | 16.35% |
| 2019 FY | -6.28 Million GBP | 22.26% |
| 2019 Q3 | -1.49 Million GBP | 54.48% |
| 2019 Q2 | -3.28 Million GBP | -100.0% |
| 2019 Q4 | -3.11 Million GBP | -108.01% |
| 2018 Q2 | -2.07 Million GBP | 0.0% |
| 2018 Q4 | -1.96 Million GBP | 0.0% |
| 2018 Q3 | -1.96 Million GBP | 5.26% |
| 2018 Q1 | -2.07 Million GBP | -2.53% |
| 2018 FY | -8.08 Million GBP | -11.7% |
| 2017 FY | -7.23 Million GBP | -9.79% |
| 2017 Q4 | -2.02 Million GBP | 0.0% |
| 2017 Q3 | -2.02 Million GBP | -26.99% |
| 2017 Q2 | -1.59 Million GBP | 0.0% |
| 2017 Q1 | -1.59 Million GBP | 4.86% |
| 2016 Q3 | -1.67 Million GBP | -3.4% |
| 2016 FY | -6.58 Million GBP | -44.4% |
| 2016 Q2 | -1.61 Million GBP | 0.0% |
| 2016 Q1 | -1.61 Million GBP | -7.06% |
| 2016 Q4 | -1.67 Million GBP | 0.0% |
| 2015 FY | -4.56 Million GBP | -33.23% |
| 2015 Q2 | -768.63 Thousand GBP | 0.0% |
| 2015 Q3 | -1.51 Million GBP | -96.83% |
| 2015 Q4 | -1.51 Million GBP | 0.0% |
| 2015 Q1 | -768.63 Thousand GBP | 4.31% |
| 2014 Q4 | -803.24 Thousand GBP | 0.0% |
| 2014 Q2 | -909.2 Thousand GBP | 0.0% |
| 2014 Q1 | -909.2 Thousand GBP | 27.06% |
| 2014 FY | -3.42 Million GBP | 19.0% |
| 2014 Q3 | -803.24 Thousand GBP | 11.65% |
| 2013 Q1 | -926.46 Thousand GBP | 16.02% |
| 2013 Q3 | -1.24 Million GBP | -34.55% |
| 2013 Q4 | -1.24 Million GBP | 0.0% |
| 2013 FY | -4.22 Million GBP | -1.27% |
| 2013 Q2 | -926.46 Thousand GBP | 0.0% |
| 2012 FY | -4.17 Million GBP | -8.84% |
| 2012 Q4 | -1.1 Million GBP | 0.0% |
| 2012 Q3 | -1.1 Million GBP | 0.0% |
| 2011 FY | -3.83 Million GBP | 8.23% |
| 2010 FY | -4.18 Million GBP | -140.59% |
| 2009 FY | 10.29 Million GBP | 325.11% |
| 2008 FY | -4.57 Million GBP | -29.68% |
| 2007 FY | -3.52 Million GBP | 0.0% |
| 2006 Q2 | - GBP | 0.0% |
| 2005 FY | -1.53 Million GBP | -5189.66% |
| 2004 FY | -29 Thousand GBP | -93.33% |
| 2003 FY | -15 Thousand GBP | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|